October 17, 2022

Access Insights Conference 2022 Breaks In-Person Attendance Records

Co-Hosted by IntegriChain and Blue Fin Group

Industry Conference Focused on Drug Commercialization Strategy and Operational Excellence 

Features Keynote William Roth, Industry Panels, and Exclusive ICyte Industry Benchmarks

Philadelphia, PA, October 17, 2022 – IntegriChain, delivering pharma’s only comprehensive data, consulting, and business process platform for market access, today announced that it has broken in-person attendance records for its Access Insights Conference 2022, now co-hosted by Blue Fin Group. The Access Insights Conference opens today at the Marriott Baltimore Waterfront. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference features industry executive and practitioner panels, exclusive ICyte Benchmarks presentations, and strategic and tactical programs focused on drug commercialization strategy and operational excellence. Keynoting the conference will be William Roth, General Manager and Managing Partner of Blue Fin Group and a recognized expert on business model development in healthcare, as he examines current industry trends and his vision for the future for commercialization trends by therapy archetype. 

“We are excited to see the continuing growth of our Access Insights Conference as we address the industry’s evolution to next-generation specialty and precision medicine,” said IntegriChain Co-Founder, President, and Chief Operating Officer Josh Halpern. “Our conference uniquely focuses on current industry trends, strategies, and data-driven commercialization tactics for approaching the new era of market access for GTN optimization, innovative contracting, patient services, channel design, and more. We are thrilled to kick off this year’s conference today with our esteemed colleagues from Blue Fin Group and welcome our customers, ecosystem partners and sponsors, and industry service providers for an exciting three days.”

About the Access Insights Conference
The three-day Access Insights Conference features leading industry experts, industry executives, benchmarks, strategies, and tactics for data-driven patient access and therapy commercialization.

Executive Summit: Day 1 of the conference features the vision for the future of therapy commercialization and access, insights from rich benchmark reports, and real-world experiences of industry leaders and practitioners. 

Topic Sessions: Day 2 will feature 24 hot topic sessions addressing the following themes and more:

• The impact of drug pricing reform on government pricing and gross-to-net
• Market trends and strategies for pharma product archetypes including specialty lite, biosimilars, specialty generics, vaccines, infusion products, and cell and gene products
• Innovation and trends in tokenization, script optimization, and gross-to-net optimization
• Industry panel perspectives on patient adherence program optimization and alternative channels

Eyes on ICyte: Day 3 is reserved for all ICyte sessions, including updates on Channel and Patient Data Products, Gross-to-Net SaaS and Managed Services, and Contracts & Pricing Managed Services.

About Blue Fin Group, an IntegriChain Company
Blue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support life sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers–primarily those commercializing their first asset or large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit https://consultbfg.com/ or follow on Twitter bluefingroup and LinkedIn.

About IntegriChain
IntegriChain delivers pharma’s only comprehensive data, consulting, and business process platform for market access departments. We provide the strategy, data, applications, and business process infrastructure for market access and therapy commercialization. More than 400 manufacturers rely on our consulting expertise and ICyte Platform to orchestrate their commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, pharmaceutical innovators can digitalize their market access operations, freeing up resources to focus on more data-driven decision support. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. We are headquartered in Philadelphia, PA, with offices in Ambler, PA; New York, NY, Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow on Twitter @IntegriChain and on LinkedIn.

Contact
Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com